---
layout: default
title: Eculizumab
parent: 僅模型預測 (L5)
nav_order: 305
evidence_level: L5
indication_count: 10
---

# Eculizumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Eculizumab: Original Indication Data Unavailable → Predicted New Indication: Cyclic Hematopoiesis

## One-Sentence Summary

Eculizumab's original approved indication could not be retrieved from the current evidence pack (regulatory license and indication text fields are empty). TxGNN predicts the drug may be effective for **Cyclic Hematopoiesis**, but this prediction is currently supported by **0 clinical trials** and **0 publications**, and the reviewer's own mechanistic assessment finds no known biological link between complement inhibition and this disease. Overall evidence quality across all 10 TxGNN-ranked candidates in this pack is very low (all rated L5), and a Blocking data gap on package insert safety information prevents any safety evaluation at this time.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available — regulatory license record exists (1 license, market status "已上市"/Marketed) but indication text field is blank in the source data |
| Predicted New Indication | Cyclic Hematopoiesis |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 (model prediction only, no clinical or literature support) |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action (MOA) data for Eculizumab is not available in the current evidence pack (flagged as a High-severity data gap, DG002). Based on general pharmacological knowledge referenced in the reviewer's rationale notes, Eculizumab acts as a terminal complement inhibitor (C5/membrane attack complex blockade); however, this general mechanism is not confirmed against a verified original-indication record in this pack.

Critically, the reviewer-provided mechanistic rationale for Cyclic Hematopoiesis explicitly concludes that there is **no known pathological connection** between this disease and complement biology: Cyclic Hematopoiesis is driven by ELANE gene mutations causing cyclic dysregulation of neutrophil elastase and disrupted granulopoiesis rhythm, a pathway with no established link to the complement cascade that Eculizumab targets. The high TxGNN score is assessed as potentially reflecting node-embedding similarity among hematologic disease clusters in the knowledge graph, rather than a genuine mechanistic relationship.

The same pattern repeats across the other nine ranked candidates in this pack (e.g., JAGN1 deficiency, X-linked SCN, CXCR2/CSF3R receptor defects) — all are congenital neutropenia or granulocyte-disorder syndromes whose underlying biology (protein trafficking, receptor signaling, apoptosis) does not intersect with terminal complement inhibition. Two candidates (ranks 4 and 10) returned literature hits, but on inspection these publications discuss Eculizumab's already-approved indications (PNH, aHUS, TMA, myasthenia gravis) rather than the candidate disease itself, and are flagged by the reviewer as likely disease-name/literature mismatches rather than genuine supporting evidence.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

*(Note: For reference, other candidates in this evidence pack — e.g., "congenital neutropenia-myelofibrosis-nephromegaly syndrome" and "primary release disorder of platelets" — did return literature hits, but these were assessed as disease-name/topic mismatches (discussing PNH, aHUS, TMA, and myasthenia gravis instead of the candidate disease) and do not constitute valid evidence for Cyclic Hematopoiesis.)*

---

## Malaysia Market Information

A registration record exists (market status: Marketed, 1 total license), but the license number, product name, dosage form, manufacturer, and approved indication text fields are all blank in the current data extract. This information should be re-queried from the source regulatory database before proceeding further.

---

## Safety Considerations

Please refer to the package insert for safety information.

*(Note: Key warnings, contraindications, and drug interaction data are all marked as data gaps in this pack. Retrieval of the official package insert (DG001, Blocking severity) is required before any safety-related decision can be made.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
All evidence for the Cyclic Hematopoiesis prediction is at Level L5 (model prediction only) — there are no clinical trials or literature specifically supporting this indication, and the mechanistic rationale itself indicates no plausible biological link between complement inhibition and this disease. Additionally, a Blocking-severity data gap (missing package insert warnings/contraindications) means this candidate cannot yet pass initial safety screening (S1), and this pattern of weak/absent evidence is consistent across all 10 TxGNN-ranked candidates in this pack.

**To proceed, the following is needed:**
- TFDA/NPRA package insert (warnings, contraindications) — currently Blocking (DG001)
- Verified mechanism of action data via DrugBank (DG002)
- Confirmed original indication and license details (regulatory data fields are currently empty)
- Independent verification of any future literature or trial hits against the exact candidate disease name, given the mismatch pattern observed in this pack
- Re-evaluation if genuine preclinical or case-level evidence specific to Cyclic Hematopoiesis emerges
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

